Abstract: The present application relates to a separator, a battery cell, a battery and an electrical apparatus, wherein the separator comprises two surfaces opposite to each other along its own thickness direction, at least one of the surface of the separator and the interior of the separator comprises a pore structure, and the separator further comprises a swellable polymer; the separator satisfies: when a pressure of 1.25 MPa is applied along the thickness direction of the separator, the compression rate ?V of the separator is ?25%.

Abstract: An electrode assembly, a secondary battery, and an electrical apparatus. The electrode assembly includes a positive electrode plate, a negative electrode plate and a separator. The positive electrode plate includes a positive electrode current collector and a positive electrode film layer arranged on at least one side surface of the positive electrode current collector. The positive electrode film layer in the present application includes a nickel-containing compound and a binder. A molar percentage content of a nickel element in the nickel-containing compound based on a total molar amount of transition elements is Y, and a mass percentage content of the binder in the positive electrode film layer is X; and it is satisfied: Y/X<53.

Abstract: The present application relates to a separator, a battery cell, a battery and an electrical apparatus, wherein the separator comprises two surfaces opposite to each other along its own thickness direction, at least one of the surface of the separator and the interior of the separator comprises a pore structure, and the separator further comprises a swellable polymer; the separator satisfies: when a pressure of 1.25 MPa is applied along the thickness direction of the separator, the compression rate ?V of the separator is ?25%.

Abstract: The present disclosure provides a superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery, and a preparation method thereof, belonging to the technical field of engineered nanovesicle drug loading systems. The superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery prepared by the preparation method acts on tumor cell lines. It is found that the superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery can specifically target tumor cells, induce tumor cell apoptosis, and inhibit tumor growth. The biological preparation significantly extends a survival time of mice and improves an efficacy of drugs against cancers.

Abstract: This application provides a battery and a charging method thereof, a battery management system, and an electric device, capable of improving charging performance of the battery. The battery includes at least one battery cell and a battery management system. A positive electrode active material of the battery cell includes LiMPO4, and M includes element Mn and element Fe. The battery management system is configured to: control the battery to perform a first constant current charging until a voltage of the battery reaches a first cutoff voltage; control the battery to perform a constant voltage charging; and control the battery to perform a second constant current charging until the voltage of the battery reaches a second cutoff voltage, where the second cutoff voltage is greater than the first cutoff voltage.

Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Abstract: A negative electrode plate, a secondary battery, and an electric apparatus. The negative electrode plate includes a current collector and a negative electrode film layer disposed on at least one side of the current collector, where the negative electrode film layer includes one or more active material layers, a negative electrode active material in the negative electrode film layer includes a first graphite negative electrode active material, a BET specific surface area of the first graphite negative electrode active material is denoted as A, and a BET specific surface area of the negative electrode active material in the negative electrode film layer is denoted as B, where A?B, or a BET specific surface area of a material forming the negative electrode film layer is denoted as B?, where A<B?.

Abstract: This application provides a battery and a charging method thereof, a battery management system, and an electric device, capable of improving charging performance of the battery. The battery includes at least one battery cell and a battery management system. A positive electrode active material of the battery cell includes LiMPO4, and M includes element Mn and element Fe. The battery management system is configured to: when an SOC of the battery is less than or equal to a preset SOC threshold, control the battery to charge based on a first charging current so as to heat the battery during a charging process; and when the SOC of the battery is greater than the SOC threshold, control the battery to charge based on a second charging current, where the first charging current is greater than the second charging current.

Abstract: This application discloses a charging method and apparatus, an electronic device, and a computer-readable storage medium, where the method includes: charging a secondary battery; and under a condition that a battery voltage of the secondary battery reaches a first cutoff voltage, performing constant-voltage charging on the secondary battery, and terminating the constant-voltage charging when a charging current of the secondary current reaches a target current; where the target current is greater than a first current, and the first current refers to a current at which a capacity of the secondary battery reaches a fully charged state during constant-voltage charging. A positive electrode active material of the secondary battery includes LiMPO4, where M includes Mn and Fe elements.

Abstract: This application discloses a charging method and apparatus, an electronic device, and a computer-readable storage medium, where the method includes: during a process of charging a secondary battery, charging the secondary battery with a first charging current until a SOC of the secondary battery reaches a preset value; and under a condition that the SOC of the secondary battery reaches the preset value, charging the secondary battery with a second charging current. A minimum value of the first charging current is greater than a maximum value of the second charging current. A positive electrode active material of the secondary battery includes LiMPO4, where M includes Mn and Fe elements.

Abstract: An electrode assembly, a battery cell, a battery, and a method and device for manufacturing an electrode assembly are provided. In some embodiments, the electrode assembly includes a positive electrode plate and a negative electrode plate. The positive electrode plate and the negative electrode plate are wound or folded to form a bend region. The positive electrode plate includes a plurality of bend portions located in the bend region. Each bend portion includes a positive current collecting layer and a positive active material layer. The positive current collecting layer is coated with the positive active material layer on at least one surface in a thickness direction of the positive electrode plate. A barrier layer is disposed between the positive current collecting layer and the positive active material layer.

Abstract: The present application relates to a separator, a battery cell, a battery and an electrical apparatus, wherein the separator comprises two surfaces opposite to each other along its own thickness direction, at least one of the surface of the separator and the interior of the separator comprises a pore structure, and the separator further comprises a swellable polymer; the separator satisfies: when a pressure of 1.25 MPa is applied along the thickness direction of the separator, the compression rate ?V of the separator is ?25%.

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Abstract: A battery system comprises: a battery pack comprising at least one battery cell, and a temperature sensor, a battery management system and a heating apparatus, wherein a positive-electrode active material of the battery cell comprises a lithium-containing transition metal phosphate, the lithium-containing transition metal phosphate at least comprising a manganese element; the temperature sensor is used for acquiring the temperature of the battery cell; and the battery management system is used for acquiring a first state parameter of the battery cell before and/or during a charging process of the battery cell, the first state parameter of the battery cell being used for generating a control instruction for the heating apparatus, and the control instruction being used for controlling the heating apparatus to heat the battery cell.

Abstract: A battery, a charging device, a battery charging method, a battery management system and an electrical apparatus. The battery comprises: at least one battery cell, a positive electrode active material of the battery cell comprising LiMPO4, and M comprising Mn element and Fe element; and the battery management system, used for controlling the temperature of the battery in response to a charging instruction, such that the temperature of the battery during at least part of a charging process is within a preset temperature range.

Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present disclosure provides use of a human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (hucMSC-sEV) in preparation of a drug for treating type 2 diabetes mellitus (T2DM), and belongs to the technical field of biomedicine. In the present disclosure, experiments have verified that the hucMSC-SEV can effectively reduce blood glucose in a db/db mouse model, improve a morphological disorder of pancreatic islets, and increase a number of ? cells. Moreover, the hucMSC-sEV can also remodel pancreatic ? cells by reversing apoptosis and dedifferentiation of the ? cells. It is confirmed that the hucMSC-sEV is an effective pharmaceutical ingredient that improves pancreatic islet functions, and can effectively ameliorate T2DM, regulate glucose homeostasis, improve a pancreatic islet structure, and increase a quality of the pancreatic islet ? cells, thereby achieving therapeutic effects from a root cause of the disease.

Abstract: A light directing arrangement (52) is provided for directing output light from a lighting unit (50), comprising an arrangement of panels (10). The panels (10) form a funnel-type structure for limiting beam spreading from a light emitting area of the lighting unit (50). At least one panel (10) has openings in opposite surfaces (14, 22), with direct light paths between the openings blocked but an air flow passage (32) is provided between the openings. In this way, forces experienced in windy conditions are reduced.

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).